U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information uniters it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10520312		
	Filing Date		2005-01-05		
	First Named Inventor Gerha		thardus E. MEKENKAMP, ET AL		
	Art Unit		1654		
	Examiner Name				
	Attorney Docket Numb	er	NL020600		

U.S. PATENTS

Examiner Cite Initial* Cite No Patent Number		Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear			
	1	5828402		1998-10-27	COLLINGS					
	2	5969748		1999-10-19	CASEMENT	ET AL				
If you wish	h to a	dd additional U.S. Pate	nt citatio	n information	please click the	Add button.		Add		_
			U.S.P	ATENT APPL	ICATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant		Releva		ines where es or Relev	
	1	20010047357	A1	2001-11-29	VAITHILINGA	AM ET AL				
If you wish	h to a	l dd additional U.S. Publ	ished Ap	plication citati	on information	please click the Ad	d button	Add		_
				FOREIGN PA	TENT DOCUM	MENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited Document	e or	where Rele	or Relevant	76
	1	0139494	wo	A1	2001-05-31	AOL.				С
	2	0963114	EP	A1	1999-08-12	LUCENT TECH IN	С			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10520312		
Filing Date		2005-01-05		
First Named Inventor Gerha		ardus E. MEKENKAMP, ET AL		
Art Unit		1654		
Examiner Name				
Attorney Docket Number		NL020600		

	3	0963114	₽	B1	1999-08-12	LUCENT TECH INC						
If you wish to add additional Foreign Patent Document citation information please click the Add button Add												
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove					
Examiner Initials*	Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item Initials* No hook, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/of country where published.											
	1	DAVIC 1.5 Specifications, TV Anytime and TV Anywhere, April 1999, pages 1-140, XP002237927										
	2 The TV-Anytime Forum, SP004V11 Content Referencing Specification, S-4 v1.1, April 2001, pages 1-42.											
If you wish to add additional non-patent literature document citation information please click the Add button Add												
EXAMINER SIGNATURE												
Examiner	Signa	ature				Date Considered						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a												

F

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10520312			
Filing Date		2005-01-05			
First Named Inventor Gerha		rdus E. MEKENKAMP, ET AL			
Art Unit		1654			
Examiner Name					
Attorney Docket Number		NL020600			

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1	1.98 to make th	ne appro	priate selection(s):
---------------	----------	-------	-----------------	----------	----------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Paul Im/	Date (YYYY-MM-DD)	2007-05-09
Name/Print	Paul Im	Registration Number	50.418

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.